CureVac NV (XTER:5CV)
€ 2.966 0.222 (8.09%) Market Cap: 682.36 Mil Enterprise Value: 167.57 Mil PE Ratio: 5.46 PB Ratio: 0.85 GF Score: 56/100

CureVac NV at Jefferies Healthcare Conference Transcript

Jun 09, 2022 / 01:30PM GMT
Release Date Price: €14.86 (-6.25%)
Eun Kyung Yang
Jefferies LLC, Research Division - MD & Senior Equity Research Analyst

Happy to conduct a fire sided chat with the CureVac, and presenting from CureVac is Pierre, CFO and Sarah, Head of IR. So thanks for joining me today this morning.

Pierre Kemula
CureVac N.V. - MD, CFO & Member of Management Board

Thank you very much.

Sarah Fakih
CureVac N.V. - VP Corporate Communications & IR

Thank you.

Eun Kyung Yang
Jefferies LLC, Research Division - MD & Senior Equity Research Analyst

Okay. So before we go in -- before we go into specific questions, can you talk -- give us a kind of overview of what CureVac is trying to achieve?

Pierre Kemula
CureVac N.V. - MD, CFO & Member of Management Board

Absolutely. Good morning, everyone. It's a pleasure to be here. So I mean, we are basically an mRNA company, right, trying to, of course, express all the value of mRNA in infectious diseases. We've announced

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot